Investigational drug · Phase 2
FB102
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Celiac Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 18, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "FB102"
First trial start
2025
Aug 4, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "FB102", any sponsor or status.
Conditions studied
As listed on its trial records.
- Celiac Disease
Approved drugs for the same conditions: Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "FB102" as an intervention, largest first.
- Randomized, Double Blind, Placebo-controlled Phase 2 Study in Adults With Celiac DiseasePivotal-lookingRecruiting
Forte Biosciences, Inc.Industry
NCT06982963 · 100 participants (planned) · Start Aug 4, 2025 · Primary completion Feb 28, 2027
Drug: FB102 · For: Celiac Disease
Sites: Melbourne, Australia
Forte Biosciences, Inc.Industry
NCT07623057 · 64 participants (planned) · Start Jun 23, 2026 · Primary completion Feb 2027
Drug: FB102 Single dose - Part A; FB102 Multiple doses - Part B and 2 more · For: Healthy Volunteer
Sites: Eastwood, Australia; Maroochydore, Australia
- A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Non-segmental VitiligoActive, not recruiting
Forte Biosciences, Inc.Industry
NCT06905873 · 64 participants (planned) · Start Mar 25, 2025 · Primary completion Dec 31, 2026
Drug: FB102; Placebo · For: Vitiligo
Sites: Darlinghurst, Australia; Kotara, Australia; Coorparoo, Australia · 6 sites in all
Forte Biosciences, Inc.Industry
NCT07205159 · 32 participants (planned) · Start Oct 23, 2025 · Primary completion Mar 10, 2027
Drug: FB102; Placebo · For: Alopecia Areata
Sites: Saint Leonards, Australia; Coorparoo, Australia; South Yarra, Australia · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Celiac Disease
- AmlitelimabSAR445229Phase 39 trials
Sanofi · Dermatitis Atopic, Coeliac Disease, Celiac Disease
- TEV-53408Phase 32 trials
Teva · Vitiligo, Celiac Disease
- Larazotide AcetatePhase 31 trial
Interlude Biopharma Co. · Celiac Disease, Celiac Disease in Adolescents
- DONQ52Phase 21 trial
Chugai Pharmaceutical · Celiac Disease
- KAN-101Phase 21 trial
Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA · Celiac Disease, Coeliac Disease
- TAK-101Phase 21 trial
Takeda · Celiac Disease
- ZED1227Phase 21 trial
Dr. Falk Pharma GmbH · Celiac Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.